Autoimmune encephalitis associated with anti-LGI1 antibody: a potential cause of neuropsychiatric systemic lupus erythematosus

ObjectiveTo investigate the clinical features and treatment outcomes of anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis in patients with SLE.MethodsBetween October 2014 and April 2024, serum or cerebrospinal fluid samples were collected from 332 patients with SLE suspected of autoimm...

Full description

Saved in:
Bibliographic Details
Published inLupus science & medicine Vol. 12; no. 1; p. e001429
Main Authors Chen, Sixian, Ren, Haitao, Fan, Siyuan, Zhang, Shangzhu, Li, Mengtao, Guan, Hongzhi
Format Journal Article
LanguageEnglish
Published England Lupus Foundation of America 18.02.2025
BMJ Publishing Group LTD
BMJ Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract ObjectiveTo investigate the clinical features and treatment outcomes of anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis in patients with SLE.MethodsBetween October 2014 and April 2024, serum or cerebrospinal fluid samples were collected from 332 patients with SLE suspected of autoimmune encephalitis. Cell-based assays were used to detect autoimmune antibodies, including anti-LGI1 antibodies. Four patients tested positive for anti-LGI1 antibodies, and their clinical, radiological and treatment data were analysed.ResultsAll four patients exhibited signs of limbic encephalitis, including short-term memory deficits, seizures and psychiatric disturbances. Two cases also presented with faciobrachial dystonic seizures. MRI findings revealed hyperintense basal ganglia lesions in two patients. Treatment with corticosteroids, intravenous immunoglobulin and mycophenolate mofetil led to significant improvement in three patients, with no relapses during a follow-up period ranging from 33 to 60 months. One patient succumbed to pneumonia despite initial improvement of neurological function.ConclusionScreening for anti-LGI1 antibodies in patients with neuropsychiatric systemic lupus erythematosus (NPSLE) is crucial when limbic encephalitis presents, as it enables timely and effective treatment, potentially improving patients’ outcomes. Additional basic and clinical research is required to clarify the pathogenic role of these antibodies in NPSLE.
AbstractList ObjectiveTo investigate the clinical features and treatment outcomes of anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis in patients with SLE.MethodsBetween October 2014 and April 2024, serum or cerebrospinal fluid samples were collected from 332 patients with SLE suspected of autoimmune encephalitis. Cell-based assays were used to detect autoimmune antibodies, including anti-LGI1 antibodies. Four patients tested positive for anti-LGI1 antibodies, and their clinical, radiological and treatment data were analysed.ResultsAll four patients exhibited signs of limbic encephalitis, including short-term memory deficits, seizures and psychiatric disturbances. Two cases also presented with faciobrachial dystonic seizures. MRI findings revealed hyperintense basal ganglia lesions in two patients. Treatment with corticosteroids, intravenous immunoglobulin and mycophenolate mofetil led to significant improvement in three patients, with no relapses during a follow-up period ranging from 33 to 60 months. One patient succumbed to pneumonia despite initial improvement of neurological function.ConclusionScreening for anti-LGI1 antibodies in patients with neuropsychiatric systemic lupus erythematosus (NPSLE) is crucial when limbic encephalitis presents, as it enables timely and effective treatment, potentially improving patients’ outcomes. Additional basic and clinical research is required to clarify the pathogenic role of these antibodies in NPSLE.
To investigate the clinical features and treatment outcomes of anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis in patients with SLE.OBJECTIVETo investigate the clinical features and treatment outcomes of anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis in patients with SLE.Between October 2014 and April 2024, serum or cerebrospinal fluid samples were collected from 332 patients with SLE suspected of autoimmune encephalitis. Cell-based assays were used to detect autoimmune antibodies, including anti-LGI1 antibodies. Four patients tested positive for anti-LGI1 antibodies, and their clinical, radiological and treatment data were analysed.METHODSBetween October 2014 and April 2024, serum or cerebrospinal fluid samples were collected from 332 patients with SLE suspected of autoimmune encephalitis. Cell-based assays were used to detect autoimmune antibodies, including anti-LGI1 antibodies. Four patients tested positive for anti-LGI1 antibodies, and their clinical, radiological and treatment data were analysed.All four patients exhibited signs of limbic encephalitis, including short-term memory deficits, seizures and psychiatric disturbances. Two cases also presented with faciobrachial dystonic seizures. MRI findings revealed hyperintense basal ganglia lesions in two patients. Treatment with corticosteroids, intravenous immunoglobulin and mycophenolate mofetil led to significant improvement in three patients, with no relapses during a follow-up period ranging from 33 to 60 months. One patient succumbed to pneumonia despite initial improvement of neurological function.RESULTSAll four patients exhibited signs of limbic encephalitis, including short-term memory deficits, seizures and psychiatric disturbances. Two cases also presented with faciobrachial dystonic seizures. MRI findings revealed hyperintense basal ganglia lesions in two patients. Treatment with corticosteroids, intravenous immunoglobulin and mycophenolate mofetil led to significant improvement in three patients, with no relapses during a follow-up period ranging from 33 to 60 months. One patient succumbed to pneumonia despite initial improvement of neurological function.Screening for anti-LGI1 antibodies in patients with neuropsychiatric systemic lupus erythematosus (NPSLE) is crucial when limbic encephalitis presents, as it enables timely and effective treatment, potentially improving patients' outcomes. Additional basic and clinical research is required to clarify the pathogenic role of these antibodies in NPSLE.CONCLUSIONScreening for anti-LGI1 antibodies in patients with neuropsychiatric systemic lupus erythematosus (NPSLE) is crucial when limbic encephalitis presents, as it enables timely and effective treatment, potentially improving patients' outcomes. Additional basic and clinical research is required to clarify the pathogenic role of these antibodies in NPSLE.
To investigate the clinical features and treatment outcomes of anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis in patients with SLE. Between October 2014 and April 2024, serum or cerebrospinal fluid samples were collected from 332 patients with SLE suspected of autoimmune encephalitis. Cell-based assays were used to detect autoimmune antibodies, including anti-LGI1 antibodies. Four patients tested positive for anti-LGI1 antibodies, and their clinical, radiological and treatment data were analysed. All four patients exhibited signs of limbic encephalitis, including short-term memory deficits, seizures and psychiatric disturbances. Two cases also presented with faciobrachial dystonic seizures. MRI findings revealed hyperintense basal ganglia lesions in two patients. Treatment with corticosteroids, intravenous immunoglobulin and mycophenolate mofetil led to significant improvement in three patients, with no relapses during a follow-up period ranging from 33 to 60 months. One patient succumbed to pneumonia despite initial improvement of neurological function. Screening for anti-LGI1 antibodies in patients with neuropsychiatric systemic lupus erythematosus (NPSLE) is crucial when limbic encephalitis presents, as it enables timely and effective treatment, potentially improving patients' outcomes. Additional basic and clinical research is required to clarify the pathogenic role of these antibodies in NPSLE.
Objective To investigate the clinical features and treatment outcomes of anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis in patients with SLE.Methods Between October 2014 and April 2024, serum or cerebrospinal fluid samples were collected from 332 patients with SLE suspected of autoimmune encephalitis. Cell-based assays were used to detect autoimmune antibodies, including anti-LGI1 antibodies. Four patients tested positive for anti-LGI1 antibodies, and their clinical, radiological and treatment data were analysed.Results All four patients exhibited signs of limbic encephalitis, including short-term memory deficits, seizures and psychiatric disturbances. Two cases also presented with faciobrachial dystonic seizures. MRI findings revealed hyperintense basal ganglia lesions in two patients. Treatment with corticosteroids, intravenous immunoglobulin and mycophenolate mofetil led to significant improvement in three patients, with no relapses during a follow-up period ranging from 33 to 60 months. One patient succumbed to pneumonia despite initial improvement of neurological function.Conclusion Screening for anti-LGI1 antibodies in patients with neuropsychiatric systemic lupus erythematosus (NPSLE) is crucial when limbic encephalitis presents, as it enables timely and effective treatment, potentially improving patients’ outcomes. Additional basic and clinical research is required to clarify the pathogenic role of these antibodies in NPSLE.
Author Ren, Haitao
Chen, Sixian
Guan, Hongzhi
Fan, Siyuan
Zhang, Shangzhu
Li, Mengtao
Author_xml – sequence: 1
  givenname: Sixian
  surname: Chen
  fullname: Chen, Sixian
  organization: Neurology, Peking Union Medical College Hospital, Beijing, China
– sequence: 2
  givenname: Haitao
  surname: Ren
  fullname: Ren, Haitao
  organization: Neurology, Peking Union Medical College Hospital, Beijing, China
– sequence: 3
  givenname: Siyuan
  surname: Fan
  fullname: Fan, Siyuan
  organization: Neurology, Peking Union Medical College Hospital, Beijing, China
– sequence: 4
  givenname: Shangzhu
  surname: Zhang
  fullname: Zhang, Shangzhu
  organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China
– sequence: 5
  givenname: Mengtao
  orcidid: 0000-0002-4171-9738
  surname: Li
  fullname: Li, Mengtao
  organization: Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China
– sequence: 6
  givenname: Hongzhi
  orcidid: 0000-0003-3903-5078
  surname: Guan
  fullname: Guan, Hongzhi
  email: pumchghz@126.com
  organization: Peking Union Medical College Hospital, Beijing, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39965877$$D View this record in MEDLINE/PubMed
BookMark eNp1kk1v1DAQhiNURD_oD-CCLHHhEvBXEpsLqipaVlqJC5wtx57tepXEwR-gvfDb8W5KaZE4-bX9zOuZ8ZxXJ5OfoKpeEfyOENa-H_KcY00x5TXGhFP5rDqjuGG16CQ-eaRPq8sYd7hAlLBO4BfVKZOybUTXnVW_rnLybhzzBAgmA_NWDy65iHSM3jidwKKfLm2RnpKr17crclS9t_sPSKPZJyhbPSCjcwTkN2iCHPwc92ZbooMzKO5jgrGIY8YIwj5tYdTJxxxfVs83eohweb9eVN9uPn29_lyvv9yurq_Wdc8JT7UFwRoKHQEJQgDTPeYdk9bwDWwaTRmVmkvac9uXikFQgiljXBrZCmEpZxfVavG1Xu_UHNyow1557dTxwIc7pUNyZgBlesabRmrApOMt63orbFHYYkqFxqR4fVy85tyPYE1pQNDDE9OnN5Pbqjv_QxEiWNuJQzZv7x2C_54hJjW6aGAY9AQ-R8VIK5iQksqCvvkH3fkcptKrI1WKJgQX6vXjlB5y-fPPBSALYIKPMcDmASFYHcZJHT9HHcZJLeNUYuolph93f1_9P_8brsDODQ
Cites_doi 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F
10.1212/NXI.0000000000000669
10.1212/NXI.0000000000000161
10.1186/s12883-022-02747-6
10.1002/ana.25908
10.1016/j.autrev.2021.102780
10.3988/jcn.2016.12.4.502
10.1136/jnnp-2021-327302
10.1016/S1474-4422(15)00401-9
10.1212/NXI.0000000000000956
10.1002/art.40356
10.1016/j.autrev.2016.07.009
10.1093/brain/awaa104
10.1212/NXI.0000000000001086
10.1093/brain/awy253
ContentType Journal Article
Copyright Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.
2025 Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group. 2025
Copyright_xml – notice: Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.
– notice: 2025 Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Copyright © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group. 2025
DBID 9YT
ACMMV
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
BTHHO
CCPQU
DWQXO
FYUFA
GHDGH
K9.
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1136/lupus-2024-001429
DatabaseName BMJ Open Access Journals
BMJ Journals:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
BMJ Journals
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals - May need to register for free articles
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
ProQuest Health & Medical Research Collection
Health Research Premium Collection
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals (DOAJ)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: ACMMV
  name: BMJ Journals:Open Access
  url: https://journals.bmj.com/
  sourceTypes: Publisher
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2053-8790
ExternalDocumentID oai_doaj_org_article_cb34559ae0174637bd8d1740d0228a01
PMC11836784
39965877
10_1136_lupus_2024_001429
lupusscimed
Genre Journal Article
GrantInformation_xml – fundername: National High Level Hospital Clinical Research Funding
  grantid: 2022-PUMCH-B-120
– fundername: ;
  grantid: 2022-PUMCH-B-120
GroupedDBID 53G
5VS
7X7
8FI
8FJ
9YT
ABUWG
ACGFS
ACMMV
ADBBV
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
BPHCQ
BTFSW
BTHHO
CCPQU
DIK
FRJ
FYUFA
GROUPED_DOAJ
H13
HMCUK
HYE
KQ8
M~E
OK1
PGMZT
PHGZT
PIMPY
PQQKQ
PROAC
RHI
RMJ
RPM
UKHRP
AAYXX
ADRAZ
CITATION
M48
PHGZM
PJZUB
PPXIY
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-b414t-de8352e71e9e88e3ab04739dc4fef5a2329a492b4db879e821023349c9688d243
IEDL.DBID M48
ISSN 2053-8790
IngestDate Wed Aug 27 01:14:55 EDT 2025
Thu Aug 21 18:28:39 EDT 2025
Thu Jul 10 22:46:07 EDT 2025
Fri Jul 25 22:02:55 EDT 2025
Mon Jul 21 06:02:06 EDT 2025
Tue Aug 05 11:57:17 EDT 2025
Thu Apr 24 22:49:35 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Antibodies
Autoimmune Diseases
Lupus Erythematosus, Systemic
Language English
License This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b414t-de8352e71e9e88e3ab04739dc4fef5a2329a492b4db879e821023349c9688d243
Notes Original research
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Report-3
ObjectType-Case Study-4
None declared.
ORCID 0000-0003-3903-5078
0000-0002-4171-9738
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1136/lupus-2024-001429
PMID 39965877
PQID 3168492110
PQPubID 2041883
ParticipantIDs doaj_primary_oai_doaj_org_article_cb34559ae0174637bd8d1740d0228a01
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11836784
proquest_miscellaneous_3168389929
proquest_journals_3168492110
pubmed_primary_39965877
crossref_primary_10_1136_lupus_2024_001429
bmj_journals_10_1136_lupus_2024_001429
PublicationCentury 2000
PublicationDate 2025-02-18
PublicationDateYYYYMMDD 2025-02-18
PublicationDate_xml – month: 02
  year: 2025
  text: 2025-02-18
  day: 18
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
– name: BMA House, Tavistock Square, London, WC1H 9JR
PublicationTitle Lupus science & medicine
PublicationTitleAbbrev Lupus Sci Med
PublicationTitleAlternate Lupus Sci Med
PublicationYear 2025
Publisher Lupus Foundation of America
BMJ Publishing Group LTD
BMJ Publishing Group
Publisher_xml – name: Lupus Foundation of America
– name: BMJ Publishing Group LTD
– name: BMJ Publishing Group
References Li, Wang, Wu (R5) 2022; 22
Wen, Stock, Chalmers (R10) 2016; 15
Lehmann-Horn, Irani, Wang (R11) 2020; 7
Varley, Andersson, Grant (R15) 2020; 88
Wu, Feng, Huang (R4) 2016; 12
Carrión-Barberà, Salman-Monte, Vílchez-Oya (R2) 2021; 20
Rodriguez, Klein, Sechi (R9) 2022; 93
Graus, Titulaer, Balu (R6) 2016; 15
Petit-Pedrol, Sell, Planagumà (R12) 2018; 141
Gritsch, Mbonde, Harahsheh (R14) 2021; 8
Ramberger, Berretta, Tan (R3) 2020; 143
Mader, Jeganathan, Arinuma (R13) 2018; 70
Flanagan, Kotsenas, Britton (R7) 2015; 2
Dürr, Nissen, Sühs (R8) 2021; 8
(R1) 1999; 42
2025070111453897000_12.1.e001429.9
Mader (2025070111453897000_12.1.e001429.13) 2018; 70
Varley (2025070111453897000_12.1.e001429.15) 2020; 88
2025070111453897000_12.1.e001429.6
2025070111453897000_12.1.e001429.1
Wu (2025070111453897000_12.1.e001429.4) 2016; 12
Flanagan (2025070111453897000_12.1.e001429.7) 2015; 2
2025070111453897000_12.1.e001429.11
Dürr (2025070111453897000_12.1.e001429.8) 2021; 8
Gritsch (2025070111453897000_12.1.e001429.14) 2021; 8
Wen (2025070111453897000_12.1.e001429.10) 2016; 15
Petit-Pedrol (2025070111453897000_12.1.e001429.12) 2018; 141
Carrión-Barberà (2025070111453897000_12.1.e001429.2) 2021; 20
Ramberger (2025070111453897000_12.1.e001429.3) 2020; 143
Li (2025070111453897000_12.1.e001429.5) 2022; 22
References_xml – volume: 42
  start-page: 599
  year: 1999
  ident: R1
  article-title: The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes
  publication-title: Arthritis & Rheumatism
  doi: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F
– volume: 7
  year: 2020
  ident: R11
  article-title: Intrathecal B-cell activation in LGI1 antibody encephalitis
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000669
– volume: 2
  year: 2015
  ident: R7
  article-title: Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000161
– volume: 22
  year: 2022
  ident: R5
  article-title: Neuropsychiatric lupus erythematosus with neurogenic pulmonary edema and anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor limbic encephalitis: a case report
  publication-title: BMC Neurol
  doi: 10.1186/s12883-022-02747-6
– volume: 88
  start-page: 1244
  year: 2020
  ident: R15
  article-title: Absence of Neuronal Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus
  publication-title: Ann Neurol
  doi: 10.1002/ana.25908
– volume: 20
  start-page: 102780
  year: 2021
  ident: R2
  article-title: Neuropsychiatric involvement in systemic lupus erythematosus: A review
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2021.102780
– volume: 12
  start-page: 502
  year: 2016
  ident: R4
  article-title: Anti-N-Methyl-D-Aspartate Receptor Encephalitis in a Patient with Systemic Lupus Erythematosus
  publication-title: J Clin Neurol
  doi: 10.3988/jcn.2016.12.4.502
– volume: 93
  start-page: 309
  year: 2022
  ident: R9
  article-title: LGI1 antibody encephalitis: acute treatment comparisons and outcome
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp-2021-327302
– volume: 15
  start-page: 391
  year: 2016
  ident: R6
  article-title: A clinical approach to diagnosis of autoimmune encephalitis
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(15)00401-9
– volume: 8
  year: 2021
  ident: R14
  article-title: Reversible Cerebral Vasculopathy, Transverse Myelitis, and Active Systemic Lupus Erythematosus in an Aquaporin-4 Antibody-Positive Patient
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000956
– volume: 70
  start-page: 277
  year: 2018
  ident: R13
  article-title: Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets?
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.40356
– volume: 15
  start-page: 890
  year: 2016
  ident: R10
  article-title: The role of B cells and autoantibodies in neuropsychiatric lupus
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2016.07.009
– volume: 143
  start-page: 1731
  year: 2020
  ident: R3
  article-title: Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms
  publication-title: Brain (Bacau)
  doi: 10.1093/brain/awaa104
– volume: 8
  year: 2021
  ident: R8
  article-title: CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune Encephalitis
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000001086
– volume: 141
  start-page: 3144
  year: 2018
  ident: R12
  article-title: LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory
  publication-title: Brain (Bacau)
  doi: 10.1093/brain/awy253
– volume: 8
  year: 2021
  ident: 2025070111453897000_12.1.e001429.14
  article-title: Reversible Cerebral Vasculopathy, Transverse Myelitis, and Active Systemic Lupus Erythematosus in an Aquaporin-4 Antibody-Positive Patient
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000956
– volume: 70
  start-page: 277
  year: 2018
  ident: 2025070111453897000_12.1.e001429.13
  article-title: Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets?
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.40356
– volume: 141
  start-page: 3144
  year: 2018
  ident: 2025070111453897000_12.1.e001429.12
  article-title: LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory
  publication-title: Brain (Bacau)
– volume: 12
  start-page: 502
  year: 2016
  ident: 2025070111453897000_12.1.e001429.4
  article-title: Anti-N-Methyl-D-Aspartate Receptor Encephalitis in a Patient with Systemic Lupus Erythematosus
  publication-title: J Clin Neurol
  doi: 10.3988/jcn.2016.12.4.502
– ident: 2025070111453897000_12.1.e001429.9
  doi: 10.1136/jnnp-2021-327302
– volume: 88
  start-page: 1244
  year: 2020
  ident: 2025070111453897000_12.1.e001429.15
  article-title: Absence of Neuronal Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus
  publication-title: Ann Neurol
  doi: 10.1002/ana.25908
– volume: 20
  start-page: 102780
  year: 2021
  ident: 2025070111453897000_12.1.e001429.2
  article-title: Neuropsychiatric involvement in systemic lupus erythematosus: A review
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2021.102780
– ident: 2025070111453897000_12.1.e001429.11
  doi: 10.1212/NXI.0000000000000669
– volume: 22
  year: 2022
  ident: 2025070111453897000_12.1.e001429.5
  article-title: Neuropsychiatric lupus erythematosus with neurogenic pulmonary edema and anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor limbic encephalitis: a case report
  publication-title: BMC Neurol
  doi: 10.1186/s12883-022-02747-6
– volume: 8
  year: 2021
  ident: 2025070111453897000_12.1.e001429.8
  article-title: CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune Encephalitis
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000001086
– volume: 2
  year: 2015
  ident: 2025070111453897000_12.1.e001429.7
  article-title: Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000161
– volume: 143
  start-page: 1731
  year: 2020
  ident: 2025070111453897000_12.1.e001429.3
  article-title: Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms
  publication-title: Brain (Bacau)
  doi: 10.1093/brain/awaa104
– volume: 15
  start-page: 890
  year: 2016
  ident: 2025070111453897000_12.1.e001429.10
  article-title: The role of B cells and autoantibodies in neuropsychiatric lupus
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2016.07.009
– ident: 2025070111453897000_12.1.e001429.1
  doi: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F
– ident: 2025070111453897000_12.1.e001429.6
  doi: 10.1016/S1474-4422(15)00401-9
SSID ssj0001213780
Score 2.3082838
Snippet ObjectiveTo investigate the clinical features and treatment outcomes of anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis in patients with...
To investigate the clinical features and treatment outcomes of anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis in patients with SLE. Between...
To investigate the clinical features and treatment outcomes of anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis in patients with SLE.OBJECTIVETo...
Objective To investigate the clinical features and treatment outcomes of anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis in patients with...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
bmj
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage e001429
SubjectTerms Adrenal Cortex Hormones - therapeutic use
Antibodies
Autoantibodies - blood
Autoantibodies - immunology
Autoimmune Diseases
Biomarker Studies
Biopsy
Brain research
Cerebrospinal fluid
Consciousness
Convulsions & seizures
Diagnostic tests
Disease
Drug dosages
Electroencephalography
Encephalitis
Glioma
Hospitals
Humans
Hyponatremia
Immunoglobulins
Immunoglobulins, Intravenous - therapeutic use
Intracellular Signaling Peptides and Proteins - immunology
Laboratories
Leukocytes
Limbic Encephalitis - blood
Limbic Encephalitis - diagnosis
Limbic Encephalitis - drug therapy
Limbic Encephalitis - immunology
Lupus
Lupus Erythematosus, Systemic
Lupus Vasculitis, Central Nervous System - blood
Lupus Vasculitis, Central Nervous System - diagnosis
Lupus Vasculitis, Central Nervous System - drug therapy
Lupus Vasculitis, Central Nervous System - immunology
Magnetic Resonance Imaging
Memory
Metabolism
Original Research
Patients
Pneumonia
Respiratory failure
Sodium
SummonAdditionalLinks – databaseName: BMJ Open Access Journals
  dbid: 9YT
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB6VIlW9IN4ECjIS4oCU7jr2xja3gigFUU6tVE6RHTs0CJLVJjn0wm9nJs4uXYQQNytxkrFnJvP59Q3AiywItyitS_3c5zRbpVLnrEq9zrw0CmX3tKJ7-jk_OZcfLxYXOzBbn4X5PiyH7tD9-BbPMxBDU9PPeDbjs0BwPjOHNC99A25SZhIyY_Pl7NqkChdKr1cvucjj-9AUMpnGx_dhD2Myxl1FAQk_tBWQRt7-v4HNP_dMXgtCx7fh1oQe2VFU9x3YCc1d2Dud1sfvwc-joW9rOvIRGLns8pJgdt0xO2kheEYzrwz7s04_vf_Ax5Jr_dVrZtmypX5Ai2SlHbrA2oqNfJebLdF1ySL1MxbGNrOwuoq8r203dPfh_Pjd2duTdMqwkDrJZZ_6QAAsKB5M0DoI6-ZSCeNLWYVqYRFtGStN5qR3WmEVGh8KIU1pcq19JsUD2G3aJjwChkjB6KzSxiGkqaS22qiFVIaHoLzhVQIvsbOLyUO6Yhx8iLwYhS1IQUVUUAKv1voolpFx41-V35DGNhWJLHu80K6-FpPvFaUTEgdONuDfR-ZCOa89luaeuH_snCdwsNb3b_kooRc2HdFRAs83t9H3aEHFNqEdYh3iJyQ5Hkbz2EiyNrIE9JbhbIm6faepL0d-bxzzCcQQ8vH_dtkT2M8oLTHlqdEHsNuvhvAUsVLvno3-8Qv7qBEs
  priority: 102
  providerName: BMJ Publishing Group Ltd
– databaseName: Directory of Open Access Journals - May need to register for free articles
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3BbtQwELWgB8QFAS0QWpArIQ5IUTexN7a5laqlVC2nVuotsuOJGgTJqkkOvfDtnbGzyy5CcOFmxZYy9szIbzz2G8be5SDcvLIu9TNf0GmVSp2zKvU699IolN1TRvfia3F6Jc-u59drpb7oTlikB44Ld1A5IRH1WkDTkYVQzmuPrZkn4hYbX27hnrcWTMXTlUwovUxjZqI4-D4uxh5tIpcphQUEKR-6H982tqPA2v8nqPn7jcm1LejkKXsyYUd-GGV-xh5A-5w9upiy49vs5-E4dA09-ABODru4IZDd9NxOOgDP6dyV42o26fnnL1louc7ffeSWL7qBrg7hHyo79sC7mge2y9WF6KbikfgZG2GiHG7vIutr14_9Drs6Ob48Ok2n-gqpk5kcUg8Ev0BlYEBrENbNpBLGV7KGem4RaxkrTe6kd1rhEIoOhZCmMoXWPpfiBdtquxZeMY44wei81sYhoKmlttqouVQmA1DeZHXC3uNil5N_9GUIPURRBmFL0koZtZKwD0t9lIvIt_G3wZ9IY6uBRJUdPqABlZMBlf8yoITtLfX9Sz4q54VTR2yUsP1VN3oepVNsC90YxxA7IcnxMprHShKEfQjtlEqY3jCcDVE3e9rmJrB7Y8QnEEHI1_9jcrvscU4Fi6mCjd5jW8PtCG8QRQ3ubXCYe6kWGpU
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwELVokRCXivIZaJGREAekqJvYG9tcUKlaCqKcqLS3yI6dNgjidJMceuG3M-N4t12EerMSS5l4Zpw3M84bQt7mjpl5pU1qZ7bAbJVIjdEitTK3XAmQ3WJF9-x7cXrOvy7mi5hw6-OxytWeGDZq6yvMkR9ggyWuMFz52F2l2DUKq6uxhcYWuY_UZWjVYiFu5VgyJuSqmJmx4uDX2I09WEbOUwwOEFhumd8_Nz5Kgbv_f4Dz33OTtz5EJ4_ITkSQ9HBS-S6559rH5MFZrJE_IX8Ox8E3-NuHo-i23SVC7aanOmrCWYrZVwpr2qTfPn_Jwsh4e_2Batr5AQ8QwRMqPfaO-poGzsv1seimohP9MwzCi1K3vJ64X30_9k_J-cnxj6PTNHZZSA3P-JBahyDMicwpJ6Vj2sy4YMpWvHb1XAPiUhoW3nBrpIApGCMyxlWlCiltztkzst361r0gFNCCknktlQFYU3OppRJzLlTmnLAqqxPyDha7jF7SlyEAYUUZhC1RK-WklYS8X-mj7CbWjbsmf0KNrSciYXa44JcXZfS_sjKMQ_CkHexAvGDCWGlhNLPI_6NnWUL2Vvq-ke_G5hLyZn0b_A-LKrp1fpzmIEchyvF8Mo-1JAD-AOAJkRC5YTgbom7eaZvLwPENcR8DHMFf3i3XK_Iwx4bE2KFG7pHtYTm6fUBJg3kdXOEvpCwTNQ
  priority: 102
  providerName: ProQuest
Title Autoimmune encephalitis associated with anti-LGI1 antibody: a potential cause of neuropsychiatric systemic lupus erythematosus
URI https://lupus.bmj.com/content/12/1/e001429.full
https://www.ncbi.nlm.nih.gov/pubmed/39965877
https://www.proquest.com/docview/3168492110
https://www.proquest.com/docview/3168389929
https://pubmed.ncbi.nlm.nih.gov/PMC11836784
https://doaj.org/article/cb34559ae0174637bd8d1740d0228a01
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED_tQ5r2gvheYVRGQjwgBZrYrW0khLppYyA6IbSi8RTZscOKRlOaRqIv_O3cOUmhqPCSWI2VXHx3ud_Z7u8AniSe235mbOR6bkCzVTKy1sjIqcQJLVF2Ryu6o_PB2Vi8u-xfbkFb3qoZwHJjakf1pMbz6-c_vi9fo8O_aiqSvLiuZlWJ6k5ERIg_0duwi4FJUkGDUYP26ymXmMtQSy1B08PvgG7XOTfeZR_2MHpjhJYUuuy3r2uhKzD8b4Klf--u_CNcnd6EGw3OZMPaMG7Blp_ehr1Rs5J-B34Oq0UxoT-HeEbOPbsiQD4pmWn05R2jOVqGIz-J3r95G4eWLdzyJTNsVixomxE-ITNV6VmRs8CMudo8PclYTRKNjfDOzM-XNUNsUVblXRifnlwcn0VNLYbIilgsIucJqnkZe-2V8tzYnpBcu0zkPu8bxGXaCJ1Y4SyOq1eUSXIudKYHSrlE8HuwMy2m_gAYYgqtklxpi-AnF8ooLftC6th76XScd-ApDnbamkIa0hQ-SIOwKSkorRXUgWetPtJZzc3xv85HpLFVR6LVDj8U8y9p46VpZrnAFMt4_E6JAZfWKYetniOWINOLO3DY6vu3fFT6C18dcVQHHq8uo5fS0ouZ-qKq-xCTIclxvzaPlSStkXVArRnOmqjrV6aTq8AEjtkhR7QhHvzzpg9hP6GKxVTCRh3CzmJe-UcIoxa2C9vyUuJRf77owu7weDT6hOejk_MPH7thaqIb3OcXmGAfGQ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbaIgEXxJtAASMBB6SoSeyNbSSEyqPs0t2eWmlvwY4dGgSbsEmE9sJP4jcyk8e2i1BvvVmJFU88M_Y3M_YMIc8jx8wo1ca3gY3RWyV8Y7TwrYwsVwJotxjRnR3F4xP-eT6ab5E_w10YPFY5rIntQm2LFH3ke1hgiSs0V96WP32sGoXR1aGERicWh271C0y26s3kA_D3RRQdfDx-P_b7qgK-4SGvfesQdDgROuWkdEybgAumbMozl400IAylYSDDrZECuqBNxBhXqYqltBFn8N1tcgU23gCNPTEX53w6IRNyCJ6GLN773pRNBZIYcR-NEQSy2-bHt41NsK0V8D-A--85zXMb38FNcqNHrHS_E7FbZMstbpOrsz4mf4f83m_qIsdrJo7iMlGeIrTPK6p7zjtL0dtLgYe5P_00CduWKezqNdW0LGo8sAQjpLqpHC0y2ubYXB_DzlPapZuGRvuj1C1XXa7Zomqqu-TkUub_HtlZFAv3gFBAJ0pGmVQGYFTGpZZKjLhQoXPCqjDzyEuY7KTXyippDR4WJy2xCXIl6bjikVcDP5Kyy_JxUed3yLF1R0zQ3T4oll-TXt-T1DAOxpp2sOLxmAljpYVWYDHfkA5Cj-wO_D6j70zGPfJs_Rr0HYM4euGKpuuDORGRjvudeKwpAbAJgFIIj8gNwdkgdfPNIj9tc4qDnckAt_CHF9P1lFwbH8-myXRydPiIXI-wGDJWx5G7ZKdeNu4xILTaPGnVgpIvl62HfwF0ak7q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9tnTTxgvimMMBIwANStCZ2YxsJoY2trGyrJsSkvQU7dlgRNKVphPrCH8Zfx10-uhWhve3Niq34kruzf-c73wG8iDy3_dTYwPVcTKdVMrDWyMCpyAktkXZHHt3jUXxwKj6e9c_W4E97F4bCKts1sVqoXZ7SGfk2FVgSmsyV7awJizjZG7yb_gyoghR5WttyGrWIHPrFLzTfirfDPeT1yyga7H9-fxA0FQYCK0IxD5wnAOJl6LVXynNje0Jy7VKR-axvEG1og5Na4aySOITsI86FTnWslIsEx_euw4Ykq6gDG7v7o5NPl054Qi5V60oNebz9vZyWBcplJAIyTQjWrtsf31a2xKpywP_g7r9Rm5e2wcEtuNngV7ZTC9xtWPOTO7B53Hjo78LvnXKej-nSiWe0aEzPCeiPC2YaOfCO0dkvQ46Og6MPw7Bq2dwt3jDDpvmcwpdwhtSUhWd5xqqMm8ug7HHK6uTT2Kg-lPnZos48mxdlcQ9Or4UD96EzySf-ITDEKlpFmdIWQVUmlFFa9oXUoffS6TDrwiv82Umjo0VSmT88TipiE-JKUnOlC69bfiTTOufHVYN3iWPLgZSuu3qQz74mjfYnqeUCTTfjcf0TMZfWKYetnqPsQ6YXdmGr5fcFfRcS34Xny27UfnLpmInPy3oMZUgkOh7U4rGkBKEnwkspu6BWBGeF1NWeyfi8yjCOVidHFCMeXU3XM9hEHUyOhqPDx3AjosrIVCpHbUFnPiv9E4Rrc_u00QsGX65bFf8CuppUhQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Autoimmune+encephalitis+associated+with+anti-LGI1+antibody%3A+a+potential+cause+of+neuropsychiatric+systemic+lupus+erythematosus&rft.jtitle=Lupus+science+%26+medicine&rft.au=Chen%2C+Sixian&rft.au=Ren%2C+Haitao&rft.au=Fan%2C+Siyuan&rft.au=Zhang%2C+Shangzhu&rft.date=2025-02-18&rft.issn=2053-8790&rft.eissn=2053-8790&rft.volume=12&rft.issue=1&rft_id=info:doi/10.1136%2Flupus-2024-001429&rft_id=info%3Apmid%2F39965877&rft.externalDocID=39965877
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2053-8790&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2053-8790&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2053-8790&client=summon